All In Biotech

Drug Trial Radar · NCT05249556

Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old

An Open-label, Single-arm, 52-week, Multicenter Phase 3 Trial to Assess Pharmacokinetics, Safety, Tolerability, and Activity of Adjunctive Ganaxolone for the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Immedica Pharma ABIndustry
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are: * The amount of the medicine that was in participants' bodies and the safety of the medicine. * Does the medicine ganaxolone lower the number of seizures when used in addition to the participant's usual anti-seizure treatment. Participants will: Take ganaxolone 3 times daily for up to 52 weeks. Visit the clinic every 3 to 5 weeks for the initial 17 weeks of the trial and thereafter every 11 to 12 weeks. The participant's caregiver will: Keep a daily diary of the participants seizures and use of anti-seizure medications, including the trial drug ganaxolone.

Conditions

  • CDKL5 Deficiency Disorder

Interventions

  • GanaxoloneDrug

    Ganaxolone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through 17 weeks
  2. Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through 17 weeks
  3. Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through 17 weeks
  4. Safety and tolerability of ganaxolone as adjunctive therapy for the treatment of seizures in participants receiving ganaxolone doses up to 63 mg/kg/dayTime frame: Baseline through to 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.